<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188548</url>
  </required_header>
  <id_info>
    <org_study_id>17502</org_study_id>
    <secondary_id>J2J-MC-JZLA</secondary_id>
    <secondary_id>2019-003581-41</secondary_id>
    <nct_id>NCT04188548</nct_id>
  </id_info>
  <brief_title>A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer</brief_title>
  <acronym>EMBER</acronym>
  <official_title>EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug LY3484356 alone or in combination with
      other anticancer therapies is safe and effective in participants with advanced or metastatic
      breast cancer or endometrial cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">April 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities</measure>
    <time_frame>Baseline through Cycle 1 (21/28 Day Cycle)</time_frame>
    <description>Number of Participants with DLTs and DLT-Equivalent Toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3484356</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3484356</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3484356</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3484356</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of LY3484356 in Combination with Other Anticancer Therapies</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)</time_frame>
    <description>PK: AUC of LY3484356 in Combination with Other Anticancer Therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies</measure>
    <time_frame>Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)</time_frame>
    <description>PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Baseline through Disease Progression or Death (Estimated up to 28 Months)</time_frame>
    <description>ORR: Percentage of Participants with Confirmed CR or PR as per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR): Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier</measure>
    <time_frame>Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 28 Months)</time_frame>
    <description>DoR: Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response (BOR) of CR, PR, and Stable Disease (SD) as per RECIST v1.1</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 28 Months)</time_frame>
    <description>DCR: Percentage of Participants with a BOR of CR, PR, and SD as per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR): Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 28 Months)</time_frame>
    <description>CBR: Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS): Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier</measure>
    <time_frame>Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 28 Months)</time_frame>
    <description>PFS: Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Escalation LY3484356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Expansion: Cohort E3: LY3484356</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 and everolimus given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 and alpelisib given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Dose Expansion: LY3484356 +/- Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3484356</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Dose Escalation LY3484356</arm_group_label>
    <arm_group_label>Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI</arm_group_label>
    <arm_group_label>Part B: Dose Expansion: Cohort E3: LY3484356</arm_group_label>
    <arm_group_label>Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus</arm_group_label>
    <arm_group_label>Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib</arm_group_label>
    <arm_group_label>Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib</arm_group_label>
    <arm_group_label>Part D: Dose Expansion: LY3484356 +/- Abemaciclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI</arm_group_label>
    <arm_group_label>Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib</arm_group_label>
    <arm_group_label>Part D: Dose Expansion: LY3484356 +/- Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpelisib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitor (AI)</intervention_name>
    <description>Anastrozole or Exemestane or Letrozole administered orally (physician choice)</description>
    <arm_group_label>Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All study parts:

          -  Participants must be willing to provide adequate archival tissue sample

          -  Participants must be willing to use highly effective birth control

          -  Participants must have adequate organ function

          -  Participants must be able to swallow capsules

        Dose escalation- Participants must have one of the following:

          -  Parts A and B: ER+ HER2- breast cancer with evidence of locally advanced unresectable
             or metastatic disease who have had the following:

          -  Part A: may have had up to 1 prior regimen of any kind for in the advanced/metastatic
             setting and no prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy.

          -  Part B: may have had up to 2 prior regimens, no more than 1 of which may be endocrine
             therapy in the advanced/metastatic setting, and must have received a prior CDK4/6
             inhibitor

          -  Cohort E4: No prior everolimus.

          -  Cohort E5: No prior alpelisib and must have a phosphatidylinositol 3-kinase catalytic
             α (PIK3Cα) mutation as determined by local testing.

          -  Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer
             with evidence of locally advanced unresectable or metastatic disease who have had at
             least 2 HER2-directed therapies for advanced disease and prior trastuzumab,
             pertuzumab, and TDM-1 required in any setting.

          -  Part D: ER+, EEC that has progressed after platinum containing chemotherapy and no
             prior fulvestrant or aromatase inhibitor therapy.

        Participants with ER+/HER2- breast cancer enrolled in this study must have had evidence of
        clinical benefit while on endocrine therapy for at least 24 months in the adjuvant setting
        or at least 6 months in the advanced/metastatic setting or have untreated de novo
        metastatic breast cancer

        Exclusion Criteria:

          -  Participants must not have certain infections such as hepatitis or tuberculosis or HIV
             that are not well controlled

          -  Participants must not have another serious medical condition

          -  Participants must not have cancer of the central nervous system that is unstable

          -  Participants must not be pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>Clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-256-6444</phone>
    </contact>
    <investigator>
      <last_name>Lida Mina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>480-342-7390</phone>
    </contact>
    <investigator>
      <last_name>Brenda Ernst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>479-587-1700</phone>
    </contact>
    <investigator>
      <last_name>Joseph T Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>310-432-8941</phone>
    </contact>
    <investigator>
      <last_name>Linnea Chap</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of California Irvine College of Medicine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>714-456-8614</phone>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>415-353-7618</phone>
    </contact>
    <investigator>
      <last_name>Hope Rugo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Frances Valdes-Albini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Center Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>4042510641</phone>
    </contact>
    <investigator>
      <last_name>Manali Ajay Bhave</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>312-503-4853</phone>
    </contact>
    <investigator>
      <last_name>Daniela Matei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>410-955-8847</phone>
    </contact>
    <investigator>
      <last_name>Jessica Tao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>617-632-5869</phone>
    </contact>
    <investigator>
      <last_name>Rinath Jeselsohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology/Hematology PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>612-884-6300</phone>
    </contact>
    <investigator>
      <last_name>Timothy G. Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>507-293-0462</phone>
    </contact>
    <investigator>
      <last_name>Karthik V Giridhar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>314-362-9383</phone>
    </contact>
    <investigator>
      <last_name>Cynthia Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>646-888-4545</phone>
    </contact>
    <investigator>
      <last_name>Komal Jhaveri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester School of Medicine</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>585-275-4401</phone>
    </contact>
    <investigator>
      <last_name>Carla Falkson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>919-668-5247</phone>
    </contact>
    <investigator>
      <last_name>Sarah L Sammons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>614-366-4741</phone>
    </contact>
    <investigator>
      <last_name>Nicole Williams</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Erika P Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>615-322-2064</phone>
    </contact>
    <investigator>
      <last_name>Ingrid Mayer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>2143701000</phone>
    </contact>
    <investigator>
      <last_name>Cynthia R.C. Osborne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9179</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-648-4180</phone>
    </contact>
    <investigator>
      <last_name>Nisha Unni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>210-656-7177</phone>
    </contact>
    <investigator>
      <last_name>Sharon T Wilks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-593-5250</phone>
    </contact>
    <investigator>
      <last_name>Muralidhar Beeram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>281-863-1000</phone>
    </contact>
    <investigator>
      <last_name>SMO US Oncology</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>903-579-9800</phone>
    </contact>
    <investigator>
      <last_name>Donald A Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>802-656-4101</phone>
    </contact>
    <investigator>
      <last_name>Peter A Kaufman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Dwight and Martha Schar Center Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>571-472-4724</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Harnden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>757-466-8683</phone>
    </contact>
    <investigator>
      <last_name>Paul Conkling</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Associates of Southwest Virginia Inc</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>540-774-8660</phone>
    </contact>
    <investigator>
      <last_name>Paul D Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>206-606-1226</phone>
    </contact>
    <investigator>
      <last_name>Kaylan Banda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61293555655</phone>
    </contact>
    <investigator>
      <last_name>Elgene Lim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6189346 3841</phone>
    </contact>
    <investigator>
      <last_name>Tarek Meniawy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussel</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3225413189</phone>
    </contact>
    <investigator>
      <last_name>Philippe Aftimos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3238213646</phone>
    </contact>
    <investigator>
      <last_name>Hans Prenen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>3216344634</phone>
    </contact>
    <investigator>
      <last_name>Patrick Neven</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>33478782644</phone>
    </contact>
    <investigator>
      <last_name>Olivier Tredan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris CEDEX 05</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>33156245500</phone>
    </contact>
    <investigator>
      <last_name>Jean-Yves Pierga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest Centre René Gauducheau</name>
      <address>
        <city>Saint Herblain Cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>33240679977</phone>
    </contact>
    <investigator>
      <last_name>Mario Campone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-Ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>81120023812</phone>
    </contact>
    <investigator>
      <last_name>Kan Yonemori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>82222288173</phone>
    </contact>
    <investigator>
      <last_name>Joo Hyuk Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>82220720850</phone>
    </contact>
    <investigator>
      <last_name>Seock-Ah Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>82230103217</phone>
    </contact>
    <investigator>
      <last_name>Sung-Bae Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34934893000-2658</phone>
    </contact>
    <investigator>
      <last_name>Cristina Saura Manich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>0034663701518</phone>
    </contact>
    <investigator>
      <last_name>Javier Garcia-Corbacho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34914269070</phone>
    </contact>
    <investigator>
      <last_name>Yolanda Jerez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34913303000 Ext.7545</phone>
    </contact>
    <investigator>
      <last_name>Elena Lopez Miranda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34913908923</phone>
    </contact>
    <investigator>
      <last_name>Luis Manso Sanchez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Jiménez Díaz-Oncology</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34915504800</phone>
    </contact>
    <investigator>
      <last_name>Bernard Gastón Doger de Spéville Uribe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34917567825</phone>
    </contact>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>34961973500</phone>
    </contact>
    <investigator>
      <last_name>Valentina Gambardella</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>886422052121 ext. 1639</phone>
    </contact>
    <investigator>
      <last_name>Hwei-Chung Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>8862353535 ext. 5181, 4273</phone>
    </contact>
    <investigator>
      <last_name>Kuo-Ting Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>886223123456 ext 67009</phone>
    </contact>
    <investigator>
      <last_name>Yen-Shen Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>886-28712121 ext. 2525</phone>
    </contact>
    <investigator>
      <last_name>Ta-Chung Chao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/2zSLrHO7ERDGXZvPbUVdZm?conditionId=295aPGThsEWwI62WQcqiC4</url>
    <description>A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

